FDA Inspection Photography: Pick Your Battles, Cover Your Bases
This article was originally published in The Rose Sheet
Executive Summary
Firms concerned about trade secrets or other confidential business information have options for resisting photography in the context of FDA inspections, but they should be prepared to be labeled "uncooperative" and could draw a warning letter identifying their offerings as adulterated.
You may also be interested in...
FDA Warning Letter Renews Concerns About Barring Inspection Photos
An FDA warning letter issued in August to OTC drug manufacturer Homeolab has revived discussion about companies' options when it comes to investigator photographs during facility inspections, prompting fresh insight from industry attorneys on the issue's legal underpinning and existing case law.
FDA Warning Letter Renews Concerns About Barring Inspection Photos
An FDA warning letter issued in August to OTC drug manufacturer Homeolab has revived discussion about companies' options when it comes to investigator photographs during facility inspections, prompting fresh insight from industry attorneys on the issue's legal underpinning and existing case law.
Think FDA Inspections Are Painful Now? These Could Be The Good Old Days
ICMAD's recent regulatory workshop offered perspective from FDA's Linda Katz and industry experts on the inspection process for cosmetics facilities under current law. It's clear that FDA inspections can be an ordeal, but that would pale in comparison to challenges that could arise under the proposed Personal Care Products Safety Act.